Cargando…

Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data

The rising prevalence of cardiovascular (CV) risk factors in Portugal has translated into more than 35,000 annual deaths due to CV diseases. We performed a multicenter observational cohort study encompassing clinical activities performed between 2000 and 2019 to characterize the CV risk profile and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavina, Cristina, Carvalho, Daniel Seabra, Pardal, Marisa, Afonso-Silva, Marta, Grangeia, Diana, Dinis-Oliveira, Ricardo Jorge, Araújo, Francisco, Taveira-Gomes, Tiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692709/
https://www.ncbi.nlm.nih.gov/pubmed/36431309
http://dx.doi.org/10.3390/jcm11226825
_version_ 1784837336296587264
author Gavina, Cristina
Carvalho, Daniel Seabra
Pardal, Marisa
Afonso-Silva, Marta
Grangeia, Diana
Dinis-Oliveira, Ricardo Jorge
Araújo, Francisco
Taveira-Gomes, Tiago
author_facet Gavina, Cristina
Carvalho, Daniel Seabra
Pardal, Marisa
Afonso-Silva, Marta
Grangeia, Diana
Dinis-Oliveira, Ricardo Jorge
Araújo, Francisco
Taveira-Gomes, Tiago
author_sort Gavina, Cristina
collection PubMed
description The rising prevalence of cardiovascular (CV) risk factors in Portugal has translated into more than 35,000 annual deaths due to CV diseases. We performed a multicenter observational cohort study encompassing clinical activities performed between 2000 and 2019 to characterize the CV risk profile and LDL-C management of patients in every CV risk category using electronic health records of a regional population in Portugal. We analyzed data from 14 health centers and 1 central hospital in the north of Portugal of patients between 40 and 80 years that had at least 1 family medicine appointment at these institutions. Living patients were characterized on 31 December 2019. CV risk assessment was computed according to the 2019 ESC/EAS Guidelines. Lipid-lowering therapy (LLT) and achievement of LDL-C targets were assessed. In total, the analysis included 78,459 patients. Patient proportions were 33%, 29%, 22%, and 17% for low, intermediate, high, and very high CV risk, respectively. Moderate-intensity statins were the most frequently used medication across all CV risk categories. High-intensity statins were used in 5% and 10% of high and very high CV risk patients, respectively. Ezetimibe was used in 6% and 10% of high and very high CV risk patients, respectively. LDL-C targets were achieved in 44%, 27%, 7%, and 3% of low, intermediate, high, and very high CV risk patients, respectively. For uncontrolled patients in the high and very high CV risk categories, a median LDL-C reduction of 44% and 53%, respectively, would be required to meet LDL-C targets. There are clear opportunities to optimize LDL-C management in routine clinical practice. The prescription of LLT according to CV risk represents an important missed treatment opportunity.
format Online
Article
Text
id pubmed-9692709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96927092022-11-26 Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data Gavina, Cristina Carvalho, Daniel Seabra Pardal, Marisa Afonso-Silva, Marta Grangeia, Diana Dinis-Oliveira, Ricardo Jorge Araújo, Francisco Taveira-Gomes, Tiago J Clin Med Article The rising prevalence of cardiovascular (CV) risk factors in Portugal has translated into more than 35,000 annual deaths due to CV diseases. We performed a multicenter observational cohort study encompassing clinical activities performed between 2000 and 2019 to characterize the CV risk profile and LDL-C management of patients in every CV risk category using electronic health records of a regional population in Portugal. We analyzed data from 14 health centers and 1 central hospital in the north of Portugal of patients between 40 and 80 years that had at least 1 family medicine appointment at these institutions. Living patients were characterized on 31 December 2019. CV risk assessment was computed according to the 2019 ESC/EAS Guidelines. Lipid-lowering therapy (LLT) and achievement of LDL-C targets were assessed. In total, the analysis included 78,459 patients. Patient proportions were 33%, 29%, 22%, and 17% for low, intermediate, high, and very high CV risk, respectively. Moderate-intensity statins were the most frequently used medication across all CV risk categories. High-intensity statins were used in 5% and 10% of high and very high CV risk patients, respectively. Ezetimibe was used in 6% and 10% of high and very high CV risk patients, respectively. LDL-C targets were achieved in 44%, 27%, 7%, and 3% of low, intermediate, high, and very high CV risk patients, respectively. For uncontrolled patients in the high and very high CV risk categories, a median LDL-C reduction of 44% and 53%, respectively, would be required to meet LDL-C targets. There are clear opportunities to optimize LDL-C management in routine clinical practice. The prescription of LLT according to CV risk represents an important missed treatment opportunity. MDPI 2022-11-18 /pmc/articles/PMC9692709/ /pubmed/36431309 http://dx.doi.org/10.3390/jcm11226825 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gavina, Cristina
Carvalho, Daniel Seabra
Pardal, Marisa
Afonso-Silva, Marta
Grangeia, Diana
Dinis-Oliveira, Ricardo Jorge
Araújo, Francisco
Taveira-Gomes, Tiago
Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title_full Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title_fullStr Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title_full_unstemmed Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title_short Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
title_sort cardiovascular risk profile and lipid management in the population-based cohort study latino: 20 years of real-world data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692709/
https://www.ncbi.nlm.nih.gov/pubmed/36431309
http://dx.doi.org/10.3390/jcm11226825
work_keys_str_mv AT gavinacristina cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT carvalhodanielseabra cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT pardalmarisa cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT afonsosilvamarta cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT grangeiadiana cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT dinisoliveiraricardojorge cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT araujofrancisco cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata
AT taveiragomestiago cardiovascularriskprofileandlipidmanagementinthepopulationbasedcohortstudylatino20yearsofrealworlddata